Publication: 4149

Publication: 4149

Enhancing Drug Development for Neuroendocrine Tumors: A novel radiomic signature to predict survival in patients enrolled in Alliance A021202

URL

Google Scholar

Citation:

Meeting Instance:: NETRF 2023
Year:: 2023
Type:: Abstract
Sub type:: Poster/Oral
Funding:: NCTN
Endpoint:: Secondary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:

Note:

Methodological:: No
Biospecimen:: Yes
SDC:: No

Parents:: None
Children:: None

Program:: OGC
Primary Committee:: GI
Sec. Committees:

Pharmas:: Novartis
Grants:: U10CA180821, U10CA180882, U24CA196171; U10CA180863 (CCTG); U10CA180888 (SWOG);

Corr. Author:
Authors:: Laurent Dercle Susan M. Geyer Timothy R. Asmis Sanja Karovic Michael Knopp Ardaman Shergill Andrew B. Nixon Spencer Behr Eileen Mary O'Reilly Jonathan R. Strosberg Jeffrey A. Meyerhardt Lawrence H Schwartz Emily K. Bergsland

Networks:: CA824, FL065, LAPS-IL057, LAPS-MA036, LAPS-NC010, LAPS-NY016, LAPS-OH007, VA002

Study: Alliance-A021202
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 2

Keywords: